1. Home
  2. ADXN vs KZIA Comparison

ADXN vs KZIA Comparison

Compare ADXN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADXN
  • KZIA
  • Stock Information
  • Founded
  • ADXN 2002
  • KZIA 1994
  • Country
  • ADXN Switzerland
  • KZIA Australia
  • Employees
  • ADXN N/A
  • KZIA N/A
  • Industry
  • ADXN Biotechnology: Pharmaceutical Preparations
  • KZIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADXN Health Care
  • KZIA Health Care
  • Exchange
  • ADXN Nasdaq
  • KZIA Nasdaq
  • Market Cap
  • ADXN 8.0M
  • KZIA 6.0M
  • IPO Year
  • ADXN N/A
  • KZIA 1999
  • Fundamental
  • Price
  • ADXN $7.36
  • KZIA $0.89
  • Analyst Decision
  • ADXN Strong Buy
  • KZIA Strong Buy
  • Analyst Count
  • ADXN 1
  • KZIA 2
  • Target Price
  • ADXN $30.00
  • KZIA $11.50
  • AVG Volume (30 Days)
  • ADXN 15.1K
  • KZIA 5.5M
  • Earning Date
  • ADXN 03-24-2025
  • KZIA 03-26-2025
  • Dividend Yield
  • ADXN N/A
  • KZIA N/A
  • EPS Growth
  • ADXN N/A
  • KZIA N/A
  • EPS
  • ADXN 0.06
  • KZIA N/A
  • Revenue
  • ADXN $701,260.00
  • KZIA $1,655,324.00
  • Revenue This Year
  • ADXN N/A
  • KZIA $806.89
  • Revenue Next Year
  • ADXN N/A
  • KZIA N/A
  • P/E Ratio
  • ADXN $1.01
  • KZIA N/A
  • Revenue Growth
  • ADXN N/A
  • KZIA 248000.00
  • 52 Week Low
  • ADXN $6.73
  • KZIA $0.89
  • 52 Week High
  • ADXN $27.90
  • KZIA $15.80
  • Technical
  • Relative Strength Index (RSI)
  • ADXN 46.90
  • KZIA 28.96
  • Support Level
  • ADXN $6.73
  • KZIA $0.90
  • Resistance Level
  • ADXN $7.90
  • KZIA $1.60
  • Average True Range (ATR)
  • ADXN 0.38
  • KZIA 0.24
  • MACD
  • ADXN -0.05
  • KZIA 0.01
  • Stochastic Oscillator
  • ADXN 39.55
  • KZIA 0.00

About ADXN Addex Therapeutics Ltd

Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Share on Social Networks: